Eloralintide is Eli Lilly's once-weekly selective amylin receptor agonist, previously known as LY3841136. It matters because its Phase 2 data put it in the same weight-loss range as the leading GLP-1 drugs while producing a notably gentler side-effect profile — and because it works through a pathway none of them use.
It is not approved, not prescribable, and not sold anywhere. Phase 3 enrollment began at the end of 2025.
🔑 Key Facts
- Up to 20.1% mean weight reduction at 48 weeks in Phase 2, against 0.4% for placebo
- It is an amylin agonist, not a GLP-1. Different hormone, different receptor, different satiety pathway
- Tolerability is the headline, not just efficacy — GI side effects tracked close to placebo in the lower-dose arms
- Once weekly, injectable, and studied in adults with obesity or overweight without type 2 diabetes
- Not available in any form. No approval, no prescription, no research-chemical version worth trusting
What Is Eloralintide?
Eloralintide is a synthetic, long-acting agonist of the amylin receptor. Amylin is a hormone co-secreted with insulin by pancreatic beta cells, and it is one of the body's genuine satiety signals — it slows gastric emptying, suppresses inappropriate glucagon release, and acts on the brainstem to end a meal.
The word doing the work in its description is selective. Pramlintide, the older amylin analog, hits both amylin and calcitonin receptors. Cagrilintide, Novo's entrant, is also non-selective. Eloralintide was designed to activate amylin receptors specifically, which is the stated basis for its cleaner tolerability.
How Eloralintide Works
GLP-1 drugs like semaglutide and tirzepatide work largely by slowing gastric emptying and acting on GLP-1 receptors in the hypothalamus. Amylin signals satiety through a different route, primarily via the area postrema in the brainstem.
Two consequences follow. First, appetite suppression arrives without leaning as hard on gastric slowing, which is the mechanism behind much of the nausea people report on GLP-1s. Second, because the pathways are separate, amylin agonists are candidates for combination with GLP-1s rather than replacement — which is exactly what Lilly and Novo are both pursuing.
Eloralintide Benefits
The cardiometabolic cluster is worth noting because it was measured in people without type 2 diabetes. Improvements in glycemic control and inflammation in that population suggest effects beyond what weight loss alone would predict, though secondary endpoints in a Phase 2 are hypothesis-generating rather than conclusive.
Phase 2 Results
The trial enrolled 263 adults with obesity, or overweight with at least one obesity-related comorbidity, and excluded people with type 2 diabetes. Every treatment arm met the primary endpoint at 48 weeks, with mean weight reductions ranging from 9.5% in the lowest arm to 20.1% in the highest, against 0.4% on placebo.
For scale: 20.1% puts the top arm in tirzepatide territory and above what semaglutide achieves in comparable trials. The caveat that matters is cross-trial comparison — different populations, durations and protocols make head-to-head claims unreliable until someone runs the actual head-to-head. See retatrutide vs tirzepatide for how these comparisons usually shake out.
Eloralintide Dosage
Eloralintide is dosed once weekly by subcutaneous injection. The Phase 2 program was a dose-ranging study with multiple arms, which is where the 9.5%-to-20.1% spread comes from — higher arms lost more.
Beyond that, there is no dosing guidance to give, and anyone offering you a specific milligram protocol is inventing it. The trial doses have not translated into an approved label, no titration schedule has been published for clinical use, and the drug does not exist outside the trial supply chain. When Phase 3 completes and a label is written, that will be the number to use.
Eloralintide Side Effects
Mild-to-moderate gastrointestinal symptoms were the most common adverse events — nausea, and the usual GI cluster that follows any drug affecting gastric handling and satiety.
The finding that generated the attention: in the lower-dose arms, GI adverse event incidence was similar to placebo. That is unusual in this drug class. GLP-1 and dual-agonist trials typically show a clear separation from placebo on nausea, and tolerability is the single most common reason people stop taking them.
Two honest caveats. Tolerability was better at lower doses, and lower doses also produced less weight loss — so the gentle profile and the 20.1% headline may not belong to the same arm. And a 263-person Phase 2 is not where rare adverse events surface. Phase 3 is. For how the established drugs compare on this, see GLP-1 side effects compared.
How It Compares
Read that table as orientation, not a ranking — the durations differ, which alone makes the percentages non-comparable. Our deeper comparison of the amylin class is in petrelintide and eloralintide, and the wider pipeline in tirzepatide vs the next-generation GLP-1 drugs.
Can You Get Eloralintide?
No, and this is the part worth being blunt about.
Eloralintide is not FDA approved. There is no prescription route, no compounding pathway, and no legitimate research-chemical supply. Any vendor listing "eloralintide" is selling you something whose identity nobody has verified — a peptide this new has no established reference standard for a third-party lab to test against.
If you want a clinician-supervised weight-loss option that exists today, the approved and compounded GLP-1s are the realistic route. What is GLP-1 covers the landscape, and survodutide and mazdutide cover the other pipeline drugs at a similar stage.
Frequently Asked Questions
This article is for educational purposes and is not medical advice. Eloralintide is an investigational drug that is not approved for use in any country and is not available for purchase. Trial results described here are from Phase 2 and may not replicate in Phase 3.